Cardiac Wire #165 April 4, 2024
CXR AI for CVD | TriClip Approved
Cardiac Wire #164 April 1, 2024
Statins’ Diabetes Debate | IPE’s Lp(a) Advantage
Cardiac Wire #163 March 28, 2024
Sotatercept’s PAH Approval | Bempedoic Acid’s Primary Expansion
Cardiac Wire #162 March 25, 2024
Wegovy Gets CVD Coverage | Ticagrelor Advantage
Cardiac Wire #161 March 21, 2024
Fasting Controversy | First BP ERA
Cardiac Wire #160 March 18, 2024
Zerlasiran’s LP(a) Potential | CRT 2024 Highlights
Cardiac Wire #159 March 14, 2024
Wegovy’s CVD Expansion | Painting Away Blockages
Cardiac Wire #158 March 11, 2024
Plastics in Our Plaque | Tendyne’s TMVR Promise
Cardiac Wire #157 March 7, 2024
PROACTIVE’s HF Impact | CAD Breakthrough
Cardiac Wire #156 March 4, 2024
First DCB Approval | Low-Risk ECGs
Cardiac Wire #155 February 29, 2024
Lipoprotein(a)’s CV Risk Thresholds | Intravascular Imaging’s PCI Advantage
Cardiac Wire #154 February 26, 2024
Radiation-Free Interventions | High Protein and CVD
Cardiac Wire #153 February 22, 2024
Transforming ADHF Decongestion | Lp(a)’s Independent Risks
Cardiac Wire #152 February 15, 2024
Big TEER Vote | HDL Theory Fails Again
Cardiac Wire #151 February 12, 2024
Bypass Surgery’s Hypertension Impact | Too Big for Donor Hearts
Cardiac Wire #150 February 8, 2024
Biosense Webster’s PFA Evidence | Zepbound’s Boundless Potential
Cardiac Wire #149 February 5, 2024
First TR Treatment | HCM’s TV Moment
Cardiac Wire #148 February 1, 2024
SAVR’s Outcomes vs. TAVR Adoption | Heart Disease Unawareness
Cardiac Wire #147 January 29, 2024
